This activity is expired and is no longer available for CME credit.


Comparing Pharmacokinetics, Efficacy, and Tolerability of Current Options for Mild-to-Moderate Ulcerative Colitis

Author(s)/Faculty: Gary R. Lichtenstein, MD
Release Date: 1/9/2015Expiration Date: 1/8/2016
Credit Type: CMENumber of Credits: 0
Content Type: MultimediaProvider:
Treatment for ulcerative colitis (UC) should induce and maintain remission of symptoms and mucosal inflammation to improve patients’ quality of life, according to ACG practice guidelines. Despite the perception that mild-to-moderate UC is a relatively benign condition, many patients experience suboptimal outcomes including frequent relapse and progression to more severe disease. Optimal patient outcomes in UC are hampered by a number of factors, including its misperception as a benign disease, inadequate clinical practice guidelines, mismatches between patient and provider perceptions, suboptimal use of therapeutic agents, and frequent medication non-adherence. This CME activity will address the barriers that impede optimal care, the expanding armamentarium of pharmacologic treatment of mild-to-moderate UC by taking into consideration differences in pharmacokinetics, efficacy and tolerability, and consequences of non-adherence in UC and strategies that improve adherence and patient outcomes.